Clinical Trial News and Research

RSS

Cranberries combat urinary tract infections

Cranberry juice, long dissed as a mere folk remedy for relieving urinary tract infections in women, is finally getting some respect.

11 Jan 2008

Trichloroethylene exposure linked to Parkinsonism

Industrial workers who worked with trichloroethylene (TCE) may face a greater risk for parkinsonism, a study by a team of University of Kentucky researchers shows.

10 Jan 2008

Trius Therapeutics starts U.S. phase I trial for Oxazolidinone antibacterial drug

Trius Therapeutics, Inc. has announced that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains.

9 Jan 2008

New method for presenting clinical trial survival data

Researchers have developed a new method for presenting clinical trial survival data that includes data from all trial participants unlike the standard method, according to a commentary published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Taranabant shows promise for weight loss in obese people

The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose weight, even at very low doses.

9 Jan 2008

Docetaxel given after doxorubicin reduces recurrence

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Trichloroethylene chemical - widely used in industry - is a risk factor for parkinsonism

Parkinson's disease, the most common neurodegenerative movement disorder caused by aging, can also be caused by pesticides and other neurotoxins.

8 Jan 2008

Oncolytics Biotech announces new reovirus, cyclophosphamide research

Oncolytics Biotech Inc. has reported that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine in Rochester, Minnesota, published the results of its work testing the antitumor efficacy and safety of various combinations of reovirus and cyclophosphamide in vivo.

8 Jan 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

Novel anti-tumor compound

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

4 Jan 2008

FDA clears first rapid blood test for MRSA

The U.S. Food and Drug Administration (FDA) has announced it has cleared for marketing the first rapid blood test for the drug-resistant staph bacterium known as MRSA (methicillin-resistant Staphylococcus aureus), which can cause potentially deadly infections.

3 Jan 2008

FDA approves Hi-Flex mobile bearing knee prostheses

Mitchell Sheinkop, M.D., will be the first in the U.S. to surgically implant the just-approved Nex Gen LPS-Flex mobile bearing knee on February 20, 2008 at the Neurologic and Orthopedic Hospital of Chicago.

3 Jan 2008

Three-drug cocktail improves outcomes in glioblastoma multiforme

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

2 Jan 2008

Fish oil benefits

It's good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer's disease.

28 Dec 2007

Study shows that antiangiogenic agent delays progression of advanced breast cancer

The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

28 Dec 2007

Personalized medicine will alter treatment of genetic disorders

One of the nation's pre-eminent genetic researchers, Eric Hoffman, PhD, of Children's Research Institute at Children's National Medical Center, predicts that in relatively short order, medicine's next innovation--individualized molecular therapies--will have the unprecedented ability to treat muscular dystrophies, and other disorders.

28 Dec 2007